<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1538">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386369</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI076</org_study_id>
    <nct_id>NCT04386369</nct_id>
  </id_info>
  <brief_title>Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS</brief_title>
  <acronym>APRV-COVID19</acronym>
  <official_title>Evaluation of Airway Pressure Release Ventilation on Oxygenation in Acute Respiratory Distress Syndrome in Adult Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases
      requiring invasive mechanical ventilation in the ICU (Intensive Care Unit).

      The investigators hypothesize that airway pressure release ventilation (APRV) could be
      beneficial in patients with ARDS secondary to SARS-COV2 viral pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung protective mechanical ventilation is the cornerstone of ARDS management, reducing the
      work of respiratory muscles and optimizing gas exchange. However, it can be the source of
      deleterious effects, grouped under the terms of ventilator induced lung injury (VILI) and
      ventilator induced diaphragm dysfunction.

      The protective ventilatory strategy has led to a significant improvement in the prognosis of
      ARDS patients, by reducing the volume of the air and oxygen mixture (lower tidal volume)
      delivered to the lungs and thus reducing the pulmonary stress and strain. However, this
      protective ventilation usually requires deep sedation and neuromuscular blockade to avoid
      deleterious patient-ventilator asynchrony.

      Airway Pressure Release Ventilation (APRV) has been proposed to reduce patient-ventilator
      asynchrony and reduce the VILI. The operating principles of APRV are based on the presence of
      two pressure levels that are kept constant. Spontaneous breathing is possible at any time at
      both pressure levels if the patient is not deeply sedated or under neuromuscular blockade.

      The investigators hypothesize that APRV mode could be beneficial on oxygenation and
      respiratory work in patients with ARDS secondary to SARS-COV2 viral pneumonia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Increase of at least 20% of the PaO2/FiO2 ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of interventions on ventilator settings</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Number of interventions by the physician on APRV settings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean blood pressure</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Variations of blood pressure in millimeters of mercury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Variations of heart rate in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in catecholamine doses</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Variations of catecholamine doses in milligrams per hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in static compliance at the end of 6 hours of APRV</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Static compliance (Cstat) defined as : Cstat = (VT/(Pplat-PEPtot)) Tidal Volume (VT), Plateau pressure (Pplat) and Total Positive End-expiratory Pressure (PEEPtot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations of minute ventilation</measure>
    <time_frame>6 hours after starting APRV</time_frame>
    <description>Minute ventilation in liters per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in static compliance 4 hours after stopping APRV</measure>
    <time_frame>4 hours after starting APRV</time_frame>
    <description>Static compliance (Cstat) defined as : Cstat = (VT/(Pplat-PEPtot)) Tidal Volume (VT), Plateau pressure (Pplat) and Total Positive End-expiratory Pressure (PEEPtot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a decrease of the PaO2/FiO2 ratio</measure>
    <time_frame>4 hours after stopping APRV</time_frame>
    <description>Percentage of patients with a decrease of the PaO2/FiO2 ratio</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>ARDS</condition>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Airway Pressure Release Ventilation</arm_group_label>
    <description>Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Airway pressure release ventilation</intervention_name>
    <description>Ventilator management strategy</description>
    <arm_group_label>Airway Pressure Release Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients admitted to the Intensive Care Unit for treatment of COVID-19 related acute
        respiratory failure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated in Nancy University Hospital between 01/04/2020 and 31/06/2020 for
             COVID-19 ARDS, requiring invasive ventilation

          -  Trial of airway pressure release ventilation during the ICU stay

        Exclusion Criteria:

          -  Patients requiring veno-venous ECMO

          -  Patients unable to complete the 6-hour APRV trial due to poor tolerance : SpO2
             decrease &lt; 90% on FiO2 70%, haemodynamic instability (MAP &lt; 65mmhg without
             vasopressors, or 0.5 mg/h increase in norepinephrine, ventilator asynchrony
             (respiratory rate &gt;35), hypercapnia (pH &lt; 7,25 or PaCO2 &gt;60mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Koszutski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de NANCY, Médecine Intensive et Réanimation Brabois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Zhou Y, Jin X, Lv Y, Wang P, Yang Y, Liang G, Wang B, Kang Y. Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome. Intensive Care Med. 2017 Nov;43(11):1648-1659. doi: 10.1007/s00134-017-4912-z. Epub 2017 Sep 22.</citation>
    <PMID>28936695</PMID>
  </reference>
  <reference>
    <citation>Nieman GF, Al-Khalisy H, Kollisch-Singule M, Satalin J, Blair S, Trikha G, Andrews P, Madden M, Gatto LA, Habashi NM. A Physiologically Informed Strategy to Effectively Open, Stabilize, and Protect the Acutely Injured Lung. Front Physiol. 2020 Mar 19;11:227. doi: 10.3389/fphys.2020.00227. eCollection 2020. Review.</citation>
    <PMID>32265734</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Airway Pressure Release Ventilation</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>APRV</keyword>
  <keyword>Acute respiratory failure</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

